Advertisement

advertisement
OIAm2, LLC The Company




Members

Gilead increases enrollment target for remdesivir trial in COVID-19 patients

advertisement
Home Blogs > Business
Apr 17 '20 | By oiam2companyadmin | Views: 45 | Comments: 0

?m=02&d=20200417&t=2&i=1515493600&w=1200

Gilead Sciences Inc on Friday increased enrollment target by 3,600 for a trial testing its experimental drug, remdesivir, in severe COVID-19 patients, a day after a media report said the drug was showing promise.
businessNews?d=yIl2AUoC8zA businessNews?i=i4iFeKK0zWQ:wCDo6qZ9B0s:F businessNews?i=i4iFeKK0zWQ:wCDo6qZ9B0s:V

Source: https://www.reuters.com/article/us-gilead-sciences-stocks/gilead-increases-enrollment-target-for-remdesivir-trial-in-covid-19-patients-idUSKBN21Z25V?feedType=RSS&feedName=businessNews

Share:
No comments
You need to sign in to comment
advertisement

Advertisement

advertisement
Google this
Tineye this
Bing this
Yandex this